US Edition
FDA Suspends U.S. License of Chikungunya Vaccine
The FDA suspended Ixchiq's US license after reports of serious adverse events in older adults, including hospitalizations and deaths, prompting Valneva to halt US sales immediately.
- US health authorities have suspended the licence for the Ixchiq vaccine against the chikungunya virus following reports of serious adverse events, the drug's French maker Valneva said.
- Valneva obtained US approval for the vaccine in 2023, but reports of side effects have prompted reviews, in particular over its use in older patients, including by the European Medicines Agency this year.
- Chikungunya is rarely fatal, though there is an increased risk of death for babies and the elderly, and symptoms, which include high fever and severe joint pain, are often debilitating.
52 Articles
52 Articles
France faces record chikungunya cases as US suspends vaccine licence
Mainland France has recorded an unprecedented rise in chikungunya cases this summer as the tiger mosquito spreads across the country. At the same time, US regulators have suspended the licence of a French-made vaccine after reports of serious side effects.
FDA Suspends License For Chikungunya Vaccine After 'Serious Adverse Events'
the Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) “believes this vaccine is not safe and that continued administration to the public would pose a danger to health,” the FDA said in a statement.
FDA Suspends License For Vaccine - Cites Over 20 Reported Serious Adverse Events * 100PercentFedUp.com * by Danielle
The Food and Drug Administration (FDA) has suspended the license for French drugmaker Valneva’s chikungunya vaccine, Ixchiq, effective immediately. The FDA’s Center for Biologics Evaluation and Research (CBER) said the suspension was based on over 20 serious adverse events. The serious adverse events included 21 hospitalizations and three deaths. According to Reuters, one fatality was directly linked to vaccine-derived encephalitis. “This vaccin…
The Chikungunya vaccine from the Austrian-French manufacturer Valneva is no longer allowed to be sold due to side effects. Valneva's share collapsed strongly.
der Standard AT
der Standard DEAccording to reports, the vaccine of the Austrian-French manufacturer Valneva caused 21 hospital admissions and three deaths
Coverage Details
Bias Distribution
- 40% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
